Stallergenes Greer and Nuance Pharma Enter Exclusive Long-term Partnership for Actair® Sublingual Immunotherapy Tablet for the Treatment of House Dust Mite Allergy in China
Stallergenes Greer, a global leader in allergy therapeutics, and Nuance Pharma, an innovation-focused biopharmaceutical company based in China, today announced they have entered into an exclusive long-term partnership agreement regarding the development and commercialisation of Actair®, Stallergenes Greer’s sublingual allergen immunotherapy (SLIT) tablet for the treatment of house dust mite (HDM) induced allergic rhinitis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903612776/en/
Under the terms of the partnership agreement, Stallergenes Greer and Nuance Pharma will work together on the development and registration of Actair® in China. Nuance Pharma would be responsible for the subsequent commercialisation of Actair® on the Chinese market.
“We are excited by the prospects of this strategic partnership for Actair® in China. By leveraging Stallergenes Greer’s strong heritage in respiratory allergen immunotherapy (AIT) and Nuance Pharma’s provenexpertise in market access as well as their established commercial platform in China, we aim to accelerate access to Actair® for patients in need. This major step forward underscores Stallergenes Greer’s determination to provide valuable evidence-based treatment options for individuals suffering from house-dust mite allergies. It also supports our broader ambition to expand the availability of our AIT treatments across more geographies, while unlocking the full potential of Actair®,” stated Dr Andreas Amrein, CEO of Stallergenes Greer.
“Respiratory disease is among Nuance's core areas of focus, and we are actively building a franchise with innovative solutions. Actair® is a perfect fit for our portfolio and strategy, as it represents a differentiated solution to address the medical needs in allergy. We look forward to a successful partnership with Stallergenes Greer, a leader in allergy therapeutics, on Actair® and beyond, to bring innovative therapies to Chinese patients” stated Mark Lotter, CEO and founder of Nuance Pharma.
Nearly 18% of China’s population suffers from HDM-induced allergic rhinitisi. Over the past five years, the number of AIT-treated patients posted double-digit growth, driven by the rising burden of HDM-induced respiratory allergies and thus highlighting the significant treatment gap. AIT has the potential to reach €1 billion within 10 years, making it the largest AIT market in the world.
Current Chinese guidelines and expert reviews recommend AIT as a first-line treatment for allergic rhinitis, particularly in moderate to severe cases. However, uptake remains limited by infrastructure and awareness hurdles. With the introduction of Actair®, Stallergenes Greer’s HDM tablet, more patients will gain access to a convenient treatment option, addressing the needs of those living with HDM-induced allergies.
Stallergenes Greer’s SLIT tablet for HDM-induced allergic rhinitis is already commercialised in 21 countries and territories with more to follow under the brand names Actair®, Orylmyte® or Aitmyte®.
With this agreement, Stallergenes Greer continues to advance its mission of improving allergy care by making immunotherapy treatments accessible in new and high-need markets.
ABOUT ALLERGIC RHINITIS
Allergic rhinitis is a worldwide disease estimated to affect around 400 to 500 million peopleii,iii, who are at higher risk of developing rhinitis exacerbation and asthma than the general population. Allergic rhinitis can include symptoms such as sneezing, a runny or itchy nose, nasal congestion and watery or itchy eyes, among others. Symptoms may be severe and can worsen over time and have a significant impact on quality of life.
ABOUT NUANCE PHARMA
Nuance Pharma is an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio. Focusing on specialty care, Nuance has established a differentiated combination of commercialised assets and innovative pipeline across respiratory, pain management, emergency care and iron deficiency anemia. With the mission to address critical unmet medical needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a global leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia as a region. For more information, please visit www.nuancepharma.com.
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, please visit www.stallergenesgreer.com.
i Zhang Y, Zhang L. Increasing prevalence of allergic rhinitis in China. Allergy Asthma Immunol Res 2019;11:156-69.
ii Bousquet J et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Suppl 86:8-160
iii Pawankar R, Canonica GW, ST Holgate ST, Lockey RF, Blaiss M. The WAO White Book on Allergy (Update. 2013)
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903612776/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
84% of Businesses Report Rising Network Outages Over Past Two Years3.9.2025 14:00:00 CEST | Press release
Ongoing rise of network outages has cost over a third of organizations between $1M and $5M in the last year, putting data centers at risk of significant disruption Nearly nine in ten organizations have experienced an increase in network outages over the past two years, with more than a quarter reporting increases of 25% to 50%, according to new research from Opengear, a Digi International company (NASDAQ, DGII, (www.digi.com). The rise in outages has cost more than a third of businesses between $1m and $5m in the past year alone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903508317/en/ Network outages are on the rise — 84% of businesses report more disruptions in the past two years, with over a third losing $1M–$5M in the last year, according to new research from Opengear. Over half of organizations also noted a 10-24% increase in outages over the two-year timeframe. The survey, designed to identify critical pain poin
MSCI Launches Private Credit Factor Model to Bring Transparency to Rapidly Growing Asset Class3.9.2025 14:00:00 CEST | Press release
Expanding MSCI’s multi-asset risk modeling suite, the new tool analyzes private credit risk within a total portfolio context MSCI Inc. (NYSE: MSCI) launched a Private Credit Factor Model to help investors overcome the lack of transparency in the asset class and better assess the long-term risks it presents in their overall portfolios. As investors continue to increase their allocations to the private credit market, they face a critical challenge: A lack of data and insights into their investments can obscure their view of risks of private investments within the context of their total portfolio. Over the past decade the explosive growth in private credit, driven by investors’ search for yield and structural shifts in capital markets, has outpaced the tools needed to manage it. And institutional investors such as pension funds are being asked by plan participants, boards and other stakeholders to shed light on these often-opaque assets. Designed to address these challenges, the Private C
SBC Medical to Participate in the H.C. Wainwright Conference & Emerging Growth Conference in September 20253.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, announced that it will participate in several prominent investor conferences throughout September 2025. SBC Medical will deliver large presentations and conduct one-on-one meetings with institutional investors. Below is a summary of the Company’s participation in investor conferences: H.C. Wainwright Conference Main Speaker: Hikaru Fukui (Head of IR) Date: Sep 8, 2025 Link: https://hcwevents.com/annualconference/ Emerging Growth Conference (Large Presentation) Main Speaker: Yuya Yoshida (Director, CFO, COO) Date: Sep 25, 2025, from 9:05 - 9:35 AM Eastern time. Link: https://goto.webcasts.com/starthere.jsp?ei=1717091&tp_key=c78a55764a&sti=sbc About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment cent
NuScale Proudly Supports TVA and ENTRA1 Energy Announcement of Landmark 6-Gigawatt Small Module Reactor (SMR) Deployment Program3.9.2025 13:59:00 CEST | Press release
Represents the Largest SMR Deployment in U.S. HistoryInitiative Advances President Trump’s Vision for U.S. Energy Security and American Leadership in Advanced Nuclear Technologies NuScale Power Corporation (NYSE: SMR), the industry-leading provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology, today announced its strong support for ENTRA1 Energy’s American landmark agreement with the Tennessee Valley Authority (TVA) to deploy up to 6 gigawatts of NuScale SMR capacity across TVA’s seven-state service region—the largest SMR deployment program in U.S. history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903569182/en/ This historic program is expected to deliver enough carbon-free, baseload electricity to power at least the equivalent of the entire Dallas-Fort Worth metropolitan area, which is essential at a time when sectors such as hyperscale datacenters, artificial intelligence (
Hilton and Small Luxury Hotels of the World™ Celebrate One-Year Anniversary of Exclusive Partnership, Now With More than 450 Hotels3.9.2025 13:01:00 CEST | Press release
More than 450 new hotels to dream about and book. 12 new countries to travel to with Hilton. A new world of luxury travel. In just one year, Hilton's (NYSE: HLT) exclusive partnership with Small Luxury Hotels of the World (SLH) has grown exponentially, adding on average more than one SLH property every week, dramatically expanding Hilton’s luxury offerings and creating new ways for Hilton Honors members to dream and redeem their Points around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903685115/en/ In just one year, Hilton's exclusive partnership with Small Luxury Hotels of the World (SLH) has grown exponentially, adding on average more than one SLH property every week, dramatically expanding Hilton’s luxury offerings and creating new ways for Hilton Honors members to dream and redeem their Points around the world. (Photo: Small Luxury Hotels of the World) The addition of SLH to Hilton’s luxury portfolio –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom